Country: Canada
Language: English
Source: Health Canada
GONADORELIN ACETATE
FERRING INC
H01CA01
GONADORELIN
3.2MG
POWDER FOR SOLUTION
GONADORELIN ACETATE 3.2MG
INTRAVENOUS
10ML VIAL
Prescription
GONADOTROPINS AND ANTIGONADOTROPINS
Active ingredient group (AIG) number: 0121867001; AHFS:
APPROVED
2010-08-27
_ _ _Pr_ _LUTREPULSE_ _®_ _ _ _Page 1 of 45 _ PRODUCT MONOGRAPH Pr LUTREPULSE ® Gonadorelin Acetate for Injection 3.2 mg/vial (0.9% Sodium Chloride for Injection (USP) (diluent) Subcutaneous (SC) Use Only Ovulatory Agent Ferring Inc. 200 Yorkland Blvd. Suite 500 North York, Ontario M2J 5C1 Date of Revision: May 17, 2016 Submission Control No: 187199 _ _ _Pr_ _LUTREPULSE_ _®_ _ _ _Page 2 of 45_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................6 DOSAGE AND ADMINISTRATION ................................................................................8 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................24 PART II: SCIENTIFIC INFORMATION ...............................................................................25 PHARMACEUTICAL INFORMATION ..........................................................................25 CLINICAL TRIALS ..........................................................................................................26 TOXICOLOGY ..................................................................................... Read the complete document